Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Ascendis Pharma Ads (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,252,127
  • Shares Outstanding, K 42,135
  • Annual Sales, $ 12,500 K
  • Annual Income, $ -153,640 K
  • 60-Month Beta 0.94
  • Price/Sales 420.30
  • Price/Cash Flow N/A
  • Price/Book 15.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.97
  • Number of Estimates 5
  • High Estimate -0.28
  • Low Estimate -1.38
  • Prior Year -1.31
  • Growth Rate Est. (year over year) +25.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.28 +21.34%
on 04/25/19
129.64 -0.52%
on 05/24/19
+20.93 (+19.37%)
since 04/24/19
3-Month
68.41 +88.51%
on 03/01/19
131.76 -2.12%
on 03/13/19
+56.97 (+79.14%)
since 02/22/19
52-Week
53.21 +142.38%
on 11/14/18
131.76 -2.12%
on 03/13/19
+62.46 (+93.92%)
since 05/24/18

Most Recent Stories

More News
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon(TM) hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone

- Provides real-world experience for switching pediatric growth hormone deficiency subjects one to 17 years old from daily growth hormone to once-weekly TransCon hGH -

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will hold a conference...

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Reports Full Year 2018 Financial Results

- Rare disease endocrinology pipeline continues to advance, with

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 3, 2019 at 4:30...

ASND : 128.96 (+3.46%)
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address unmet medical needs, today announced that the company will hold a conference...

ASND : 128.96 (+3.46%)
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.

ASND : 128.96 (+3.46%)
RHHBY : 34.0000 (+0.74%)
PFE : 41.95 (+0.07%)
SNY : 42.28 (+0.40%)
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address unmet medical needs, today announced a study evaluating impact of hypoparathyroidism...

ASND : 128.96 (+3.46%)
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon(TM) hGH to a Daily Growth Hormone

- Oral presentation of results in pediatric growth hormone deficiency on behalf of investigators at ENDO 2019 -

ASND : 128.96 (+3.46%)
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock

Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ASND : 128.96 (+3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ASND with:

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

2nd Resistance Point 132.79
1st Resistance Point 130.88
Last Price 128.96
1st Support Level 125.81
2nd Support Level 122.65

See More

52-Week High 131.76
Last Price 128.96
Fibonacci 61.8% 101.75
Fibonacci 50% 92.48
Fibonacci 38.2% 83.21
52-Week Low 53.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar